NCT03055494: A reported trial by Novartis Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03055494 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 18, 2017 |
| Completion date | April 25, 2018 |
| Required reporting date | April 25, 2021, midnight |
| Actual reporting date | Feb. 25, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |